Anavex Life Sciences is a clinical-stage biopharmaceutical company developing oral therapies for neurodegenerative and neurodevelopmental diseases.
Meet Anavex’s executive leadership and scientific advisors, whose experience in drug development, clinical research, and regulatory science guides the Company’s strategic direction.
Prof. Dr. Marwan Sabbagh, MD, is a behavioral neurologist in the Alzheimer’s and Memory Disorders Program at Barrow Neurological Institute....
Terrie Kellmeyer, PhD, Interim Chief Executive Officer, brings over 29 years of experience in the pharmaceutical industry and has held...
Dr. Jiong Ma brings deep financial, transactional and capital markets expertise to the Board, with substantial experience investing in, partnering...
Ms. Boenisch is a Chartered Professional Accountant (CPA, CGA) who brings nearly two decades of accounting, audit, and financial reporting...
Prof. Dr. Grimmer is a board-certified psychiatrist and psychotherapist and an Associate Professor working as a Specialist Registrar at the...
Dr. Claus van der Velden brings accounting and executive financial experience to the Board that provides critical perspective on accounting...
At Anavex Life Sciences, our work is driven by rigorous research, cross-functional collaboration, and a shared commitment to addressing unmet medical needs. We bring together scientists, clinicians, and professionals across disciplines to support the development of innovative oral therapeutic programs.
We recognize that disease progression and treatment response vary across individuals. Our research and development approach emphasizes precision strategies designed to address underlying biological mechanisms and patient variability.
Patients and caregivers provide essential insight into disease impact and treatment priorities. We value collaboration with patient communities and integrate real-world perspectives into our research and development process.
Our development programs are grounded in translational science and supported by data-driven decision-making across discovery, clinical research, and regulatory pathways.
We are committed to fostering an inclusive workplace and supporting the development of therapies intended to serve diverse patient populations worldwide.
Toll-free: 1 (844) 689-3939
ir@anavex.com
media@anavex.com
